Waters delivered 10% organic revenue growth in the third quarter and raised its full-year guidance. Bernstein believes improving business in China, acquisition synergies and orders tied to pharmaceutical manufacturing returning to the US leave room for upside to the company’s cautious 2027 framework.
Life sciences drove Revvity's third-quarter organic growth and margin above market consensus, and the company raised its full-year guidance. Bernstein says AI demand's contribution is difficult to quantify separately and maintains its Market Perform rating on valuation grounds.
Fiserv’s merchant business and Clover growth were weak in the third quarter, but financial solutions performed better than expected. The company plans to repurchase $500 million in the fourth quarter and has doubled its long-term cost savings target; meeting full-year guidance depends on a significant acceleration in the merchant business.
Amgen’s growth products offset some declines in older drugs, and the company raised its full-year revenue and earnings-per-share guidance; Bernstein believes one-time sales benefits and expense timing also boosted third-quarter performance.
Europe enters the winter of 2026/27 with gas storage levels below those of a year earlier. Bernstein believes that even if liquefied natural gas imports return to their historical monthly peak and demand remains stable, inventories will still be at historically low levels at the end of the heating season; a cold winter combined with insufficient imports could create a supply shortfall.
Combining satellite fire detections with news reports, Bernstein estimates that Russian refineries affected by recent fires account for approximately 1.5 million barrels per day of refining capacity; global refining disruptions could persist if Russia and Ukraine do not reach a peace agreement or ceasefire.
Payments and merchant services drove revenue growth faster than GMV, but a rising share of lower-margin business and AI investment weighed on overall gross margin. Bernstein sees opportunity in AI shopping entry points and raised its price target to $165.
Data center demand and Boyd drove better-than-expected performance in the global electrical business, and Eaton raised its full-year growth guidance; however, the Americas electrical margin and overall full-year growth guidance remain below market expectations.
According to media reports, CVS is preparing to split into two publicly traded companies. Bernstein believes the move could sharpen business focus but may sacrifice pharmacy synergies, and cannot directly eliminate investors’ near-term concerns about the pharmacy benefit management business.
Bloom’s backlog is growing faster than revenue, and its product gross margin is approaching 40%; Bernstein is more confident in execution but sees the conversion of orders into revenue, cash collection and long-term unit economics as key to valuation.
Bernstein estimates the present value of 3M’s PFAS-related payments at approximately 5.8 billion dollars, well above its previous expectations, but payments extend through 2034, and the agreement is expected to reduce uncertainty surrounding major litigation. Future personal injury claims and other lawsuits remain to be addressed.
Reflexivity aims to shift investment research from passive searching to proactive discovery: the platform connects market data, asset relationships and user holdings to generate event alerts, thematic portfolios and risk analysis. The company says query costs have fallen by approximately 70% over the past three months.
US CPI inflation rose to 3.7% year over year in September. Real wage growth continues to support spending, but lower-income households face greater pressure from energy costs. Bernstein expects consumers to remain focused on value for money, with varying effects on retail, restaurants and home improvement.
North American heavy-duty truck production surged in September, but new orders shifted to a year-on-year decline; construction equipment demand was supported by data center and power projects, while farm equipment sales and farmer confidence remained under pressure.
Bernstein raised its forecast for demand for Advantest SoC testers in the fiscal year ending March 2029 by 82% and lifted its price target from 45,800 yen to 55,700 yen. The key drivers of the new model are longer ASIC test times, growing shipments and an expanding server CPU testing market.
Pfizer’s third-quarter revenue was broadly flat year over year, while profit exceeded market expectations; growth products still account for a small share, and long-term growth depends on progress in the obesity and oncology pipelines.
From 2024 to 2026, US department-store points of sale for comparable brands fell 15%, while street locations increased 6%. Bernstein believes brands still have room to enter affluent, underserved areas while streamlining overlapping points of sale.
Digitization allows a single outdoor location to carry more advertisements and opens up programmatic buying channels; however, rents, capital expenditure and competition for concession renewals limit returns. Bernstein maintains its Market Perform ratings on JCDecaux and Ströer.
AMD’s third-quarter revenue and adjusted earnings per share both exceeded market consensus. Its fourth-quarter revenue guidance also beat expectations, but the outlook shows a clear divergence between accelerating data center growth and a declining PC business; inventory rose while cash flow weakened.
Arista’s third-quarter revenue and earnings per share both exceeded market consensus, and its fourth-quarter guidance was also above expectations. Bernstein is focused on its share of AI networking, enterprise IT spending, and the company’s outlook for 2027.